Received Sep 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Fainted; This serious case was reported by a consumer via call center representative and described the occurrence of fainting in a female patient who received Herpes zoster (Shingrix) for prophylaxis. On 13-MAR-2024, the patient received the 1st dose of Shingrix. On 14-MAR-2024, 1 days after receiving Shingrix, the patient experienced fainting (Verbatim: Fainted) (serious criteria GSK medically significant). On 14-MAR-2024, the outcome of the fainting was unknown. It was unknown if the reporter considered the fainting to be related to Shingrix. The company considered the fainting to be unrelated to Shingrix. Additional Information: GSK Receipt Date: 16-MAR-2024 The reporter reported this adverse event experienced by her neighbor over one year ago. 1 day after vaccination, in the morning, the patient fainted. This was all the information known at this time.; Sender's Comments: A case of Syncope, 1 day after receiving 1st dose of Shingrix in a female subject. Based on the available information a possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow up has not been received.